Reference | N. pts | Patients’ selection | Surgical approach | IORT dose (Gy) | Technique | Adjuvant EBRT | BRFS | Overall survival | Toxicity |
---|---|---|---|---|---|---|---|---|---|
Krengli (ISIORT) [2] | 108 | Intermediate-high riska | NA | 8-15 Gy with EBRT 18–21 Gy single shoot | IORT or 50-KV | NA | NA | NA | NA |
Krengli [53] | 38 | Intermediate-high riska | Retropubic approach IORT + Prostatectomy | 10-12 Gy | IORT | 46-50 Gy, 2 Gy/fx | 82% | 2-years 100% | Lymphocele 16% hematoma 6% |
Rocco [54] | 33 | Intermediate-high riska | Retropubic approach IORT + Prostatectomy | 12 Gy | IORT | 45 Gy, 1.8 Gy/fx | 97% | 2-years 100% | GU: 17% ≥ G2 GI: 10% ≥ G2 |
Saracino [55] | 34 | Intermediate riska | Retropubic approach Prostatectomy + IORT | 16-22 Gy | IORT | No | 77% | NA | No GU/GI toxicities ≥ G1 |
Orecchia [56] | 11 | High-riska | Retropubic approach IORT + Prostatectomy | 12 Gy | IORT | 45 Gy, 1.8 Gy/fx | NA | NA | No GU/GI toxicities ≥ G1 |
Kato [57] | 54 | Stage B2-D1b | Perineal/retropubic No prostatectomy | 25-30 Gy | IORT | 30 Gy, 2 Gy/fx | 74% | NA | Early GI G3: 7% |
Higashi [58] | 35 | Stage B-C b | Perineal/retropubic No prostatectomy | 25-30 Gy | IORT | 30 Gy, 2 Gy/fx | NA | 5-years 87% (stage C) 5-years 92% (stage B) | NA |
Abe [59] | 21 | Stage B2-days b | Perineal | 28-35 Gy or 20–25 Gy (if combined with EBRT) | IORT | 50 Gy | NA | 5-years 72% | GU: 100% early ematuria 10% early pollakiuria |
Kojima [60] | 30 | Stage B-C b | Perineal/retropubic No prostatectomy | -- | IORT | NA | NA | 5-years 43% | NA |
Takahashi [61] | 14 | Stage B2-days b | Perineal No prostatectomy | 28-35 Gy or 20–25 Gy (if combined with EBRT) | IORT | 50 Gy | NA | NA | 0% |